Log in Free sign up

Oncocyte (OCX) News and press releases

News

From Benzinga Pro

Oncocyte Presents DetermaIO Data At ASCO 2022 Supporting Test's Potential To Expand Clinical Use Of Immunotherapy

Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights that inform critical decisions throughout the patient care journey,

Stocks That Hit 52-Week Lows On Tuesday

News, Options, Intraday Update, Markets, Movers, Trading Ideas

On Tuesday, 540 companies set new 52-week lows.

Benzinga's Top Ratings Upgrades, Downgrades For May 24, 2022

Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings

Stephens & Co. Downgrades OncoCyte to Equal-Weight

News, Downgrades, Analyst Ratings

Stephens & Co. analyst Mason Carrico downgrades OncoCyte (NASDAQ:OCX) from Overweight to Equal-Weight.

Piper Sandler Maintains Overweight on OncoCyte, Lowers Price Target to $1.4

News, Price Target, Analyst Ratings

Piper Sandler analyst David Westenberg maintains OncoCyte (NASDAQ:OCX) with a Overweight and lowers the price target from $1.8 to $1.4.

Expert Ratings for OncoCyte

Analyst Ratings

Within the last quarter, OncoCyte (NASDAQ:OCX) has observed the following analyst ratings:

Needham Maintains Buy on OncoCyte, Lowers Price Target to $2.25

News, Price Target, Analyst Ratings

Needham analyst Mike Matson maintains OncoCyte (NASDAQ:OCX) with a Buy and lowers the price target from $4 to $2.25.

OncoCyte: Q1 Earnings Insights

OncoCyte (NASDAQ:OCX) reported its Q1 earnings results on Wednesday, May 11, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings OncoCyte reported in-line EPS of $-0.12 versus an estimate of $-0.12.

Earnings Scheduled For May 11, 2022

Earnings, News, Pre-Market Outlook, Markets

Companies Reporting Before The Bell • Great Elm Capital (NASDAQ:GECC) is expected to report earnings for its first quarter.

Stocks That Hit 52-Week Lows On Monday

News, Options, Intraday Update, Markets, Movers, Trading Ideas

On Monday, 721 companies achieved new lows for the year.

12 Health Care Stocks Moving In Wednesday's After-Market Session

2 Stocks Under $2 Insiders Are Aggressively Buying

Long Ideas, News, Penny Stocks, Insider Trades, Markets, Trading Ideas

Gold futures traded lower this morning on Tuesday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

4 Stocks Under $5 Insiders Are Aggressively Buying

Long Ideas, News, Penny Stocks, Insider Trades, Markets, Trading Ideas

US crude oil futures traded lower on Monday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

The Daily Biotech Pulse: Pfizer-BioNTech COVID-19 Booster Data In Kids, Regeneron's COVID-19 Therapy Decision Pushed, Protagonist's Rusfertide Breakthrough Tag Update And More

Biotech, Government, News, Penny Stocks, Health Care, Financing, Offerings, Small Cap, FDA, General

Here's a roundup of top developments in the biotech space over the last 24 hours:

Press releases

From Benzinga Pro

Oncocyte Hosting Key Opinion Webinar on the Role of DetermaIO and the Tumor Microenvironment in Clinical Practice

Health Care, Press Releases

IRVINE, Calif., June 22, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NASDAQ:OCX), is a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights that inform

Oncocyte Presents DetermaIO™ Data at ASCO 2022 Supporting the Test's Potential to Expand the Clinical Use of Immunotherapy

News, Health Care, Press Releases

DetermaIO identifies responders to immunotherapy among the 95% of patients with colon cancer currently ineligible for treatment based on existing biomarker, addressing a significant unmet need DetermaIO test now

Oncocyte to Announce First Quarter 2022 Financial Results

News, Press Releases

IRVINE, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights that inform critical

Oncocyte to Present New Data at ASCO 2022 Underpinning Pan-Cancer Clinical Utility of DetermaIO™

News, Health Care, Press Releases

IRVINE, Calif., April 27, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation��(NASDAQ:OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights that inform critical

Oncocyte Corporation Announces Pricing of Public Offering of Common Stock and Warrants

News, IPOs, Press Releases

IRVINE, Calif., April 13, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NASDAQ:OCX), ("Oncocyte" or the "Company"), announced today the pricing of an underwritten public offering of 26,266,417 shares of its common

Oncocyte Corporation Announces Proposed Public Offering of Common Stock and Warrants

News, Financing, Press Releases

IRVINE, Calif., April 13, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NASDAQ:OCX), ("Oncocyte" or the "Company"), announced today that it has commenced an underwritten public offering of shares of its common stock,

Oncocyte Corporation Announces Pricing of Registered Direct Offering of 11,765 Shares of Series A Convertible Preferred Stock

Markets, Press Releases

IRVINE, Calif., April 13, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NASDAQ:OCX), ("Oncocyte" or the "Company"), a precision diagnostics company with the mission to improve patient outcomes by providing